Nivolumab combined with brentuximab vedotin (BV) for relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL): Efficacy and safety results from the phase 2 CheckMate 436 study Meeting Abstract
| Authors: | Zinzani, P. L.; Santoro, A.; Gritti, G.; Brice, P.; Barr, P. M.; Kuruvilla, J.; Cunningham, D.; Kline, J.; Johnson, N. A.; Mehta-Shah, N. A.; Manley, T.; Francis, S.; Sharma, M.; Moskowitz, A. J. |
| Abstract Title: | Nivolumab combined with brentuximab vedotin (BV) for relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL): Efficacy and safety results from the phase 2 CheckMate 436 study |
| Meeting Title: | 7th Annual Meeting of the Society of Hematologic Oncology (SOHO 2019) |
| Keywords: | lymphoma; relapsed/refractory; hodgkin; brentuximab vedotin; nivolumab; hl; primary mediastinal large b-cell lymphoma (pmbl); pmbl |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 19 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Sep 11-14 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2019-09-01 |
| Start Page: | S303 |
| Language: | English |
| ACCESSION: | WOS:000483480700298 |
| DOI: | 10.1016/j.clml.2019.07.262 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: HL-078 -- Source: Wos |
